Abstract
Cancer-associated malnutrition results from a deadly combination of anorexia, which leads to reduced food intake, and derangements of host metabolism inducing body weight loss, and hindering its reversal with nutrient supplementation. Cancer patients often experience both anorexia and weight loss, contributing to the onset of the clinical feature named as anorexia–cachexia syndrome. This condition has a negative impact upon patients’ nutritional status. The pathogenesis of the anorexia–cachexia syndrome is multifactorial, and is related to: tumour-derived factors, host-derived factors inducing metabolic derangements, and side effects of anticancer therapies. In addition, the lack of awareness of cancer patients’ nutritional issues and status by many oncologists, frequently results in progressive weight loss going undiagnosed until it becomes severe. The critical involvement of host inflammatory response in the development of weight loss, and, in particular, lean body mass depletion, limits the response to the provision of standard nutrition support. A novel nutritional and metabolic approach, named “parallel pathway”, has been devised that may help maintain or improve nutritional status, and prevent or delay the onset of cancer cachexia. Such an approach may improve tolerance to aggressive anticancer therapies, and ameliorate the functional capacity and quality of life even in advanced disease stages. The “parallel pathway” implies a multiprofessional and multimodal approach aimed at ensuring early, appropriate and continuous nutritional and metabolic support to cancer patients in any phase of their cancer journey.
Similar content being viewed by others
References
MacDonald N, Easson AM, Mazurak VC et al (2003) Understanding and managing cancer cachexia. J Am Coll Surg 197:143–161
Muscaritoli M, Anker SD, Argilés J et al (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia–anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr (Epub ahead of print)
Bossola M, Muscaritoli M, Costelli P, Grieco G, Monelli G, Pacelli F, Rossi Fanelli F, Doglietto GB, Baccino FM (2003) Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237:384–389
Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, Argiles J, Lopez-Soriano FJ, Civello IM, Baccino FM, Rossi Fanelli F, Doglietto GB (2001) Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol 280:R1518–R1523
Laviano A, Meguid MM, Rossi Fanelli F (2003) Cancer anorexia: clinical implications, pathogenesis and therapeutic strategies. Lancet Oncol 4:686–694
Laviano A, Meguid MM, Rossi Fanelli F (2003) Improving food intake in anorectic cancer patients. Curr Opin Clin Nutr Metab Care 6:421–426
Argiles JM, Lopez-Soriano FJ (1998) Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1:245–251
Dempsey DT, Knox LS, Mullen JL, Miller C, Feurer ID, Buzby GP (1996) Energy expenditure in malnourished patients with colorectal cancer. Arch Surg 121:789–795
Gibney E, Elia M, Jebb SA, Murgatroyd P, Jennings G (1997) Total energy expenditure in patients with non small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism 46:1412–1417
Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219:325–331
Rossi Fanelli F, Cangiano C, Muscaritoli M, Conversano L, Torelli GF, Cascino A (1995) Tumor induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition 11:595–600
Mathupala SP, Rempel A, Pendersen PL (1995) Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 270:16918–16925
De Blaauw I, Deutz NE, von Meyenfeldt MF (1997) Metabolic changes of cancer cachexia-first of two part. Clin Nutr 16:169–176
Tajek JA, Manglik S, Abemayor E (1997) Insulin secretion, glucose production and insulin sensitivity in underweight and normal weight volunteers, and in underweight and normal-weight cancer patients. Metabolism 46:140–145
Skolnik EY, Marcusohn J (1996) Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Cytokine Growth Fact Rev 7:161–173
Halton JM, Nazir DJ, McQueen MJ, Barr RD (1998) Blood lipid profiles in children with acute lymphoblastic leukaemia. Cancer 83:379–384
Costelli P, Tessitore L, Batetta B et al (1999) Alterations of lipid and cholesterol metabolism in cachectic tumor-bearing rats are prevented by insulin. J Nutr 129:700–706
Muscaritoli M, Cangiano C, Cascino A, Ceci F, Giacomelli L, Cardelli-Cangiano P, Mulieri M, Rossi Fanelli F (1990) Plasma clearance of exogenous lipids in patients with malignant disease. Nutrition 6:147–151
Sakurai Y, Klein S (1998) Metabolic alterations in patients with cancer: nutritional implications. Surg Today 28:247–257
Ishiko O, Nishimura S, Yasui T et al (1999) Metabolic and morphologic characteristics of adipose tissue associated with the growth of malignant tumors. Jpn J Cancer Res 90:655–659
Gullett N, Rossi P, Kucuk O, Johnstone PA (2009) Cancer-induced cachexia: a guide for the oncologist. J Soc Integr Oncol 7:155–169
Korber J, Pricelius S, Heidrich M, Muller MJ (1999) Increased lipid utilization in weight losing and weight stable cancer patients with normal body weight. Eur J Clin Nutr 53:540–545
Fearon KCH (1992) The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 51:251–265
López-Soriano J, Carbó N, Tessitore L, López-Soriano FJ, Argilés JM (1999) Leptin and tumor growth in rats. Int J Cancer 81:726–729
Wallace AM, Sattar N, McMillan DC (1998) Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res 4:2977–2979
Costelli P, Baccino FM (2000) Cancer cachexia: from experimental models to cancer patients. Curr Opin Clin Nutr Metab Care 3:177–181
Kadowaki M, Kanazawa T (2003) Amino acids as regulators of proteolysis. J Nutr 133:2052S–2056S
Temparis S, Asensi M, Taillandier D et al (1994) Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 54:5568–5573
Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, Argiles JM (1995) Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 61:138–141
Lundholm K, Ekman L, Karlberg I, Edstrom S, Schersten T (1980) Comparison of hepatic cathepsin D activity in response to tumor growth and to caloric restriction in mice. Cancer Res 40:1680–1685
Tessitore L, Costelli P, Bonetti G, Baccino FM (1993) Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 306:52–58
Deval C, Mordier S, Obled C et al (2001) Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem J 360:143–150
Jagoe RT, Redfern CP, Roberts RG, Gibson GJ, Goodship TH (2002) Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin Sci 102:353–361
Costelli P, De Tullio R, Baccino FM, Melloni E (2001) Activation of Ca2+-dependent proteolysis in the skeletal muscle and heart in cancer cachexia. Br J Cancer 84:946–950
Costelli P, Bossola M, Muscaritoli M et al (2002) Anti-cytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca2+-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine 19:1–5
Wray CJ, Sun X, Gang GI, Hasselgren PO (2002) Dantrolene downregulates the gene expression and activity of the ubiquitin-proteasome proteolytic pathway in septic skeletal muscle. J Surg Res 104:82–87
Tidball JG, Spencer MJ (2002) Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J Physiol 545:819–828
Guttridge DC, Mayo MW, Madrid LW et al (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289:2363–2366
Sabourin LA, Rudnicki MA (2000) The molecular regulation of myogenesis. Clin Genet 57:16–25
Costelli P, Muscaritoli M, Bossola M et al (2005) Skeletal muscle wasting in tumour-bearing rats is associated with MyoD down-regulation. Int J Oncol 26:1663–1668
Costelli P, Muscaritoli M, Bonetto A et al (2008) Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 38:531–538
Van Royen M, Carbo N, Busquets S, Alvarez B, Quinn LS, Lopez-Soriano FJ et al (2000) DNA fragmentation occurs in skeletal muscle during tumour growth: a link with cancer cachexia? Biochem Biophysic Res Commun 270:533–537
Bossola M, Mirabella M, Ricci E, Costelli P, Pacelli F, Tortorelli AP, Muscaritoli M, Rossi Fanelli F, Baccino FM, Tonali PA, Doglietto GB (2006) Skeletal muscle apoptosis is not increate in gastric cancer patients with mild-moderate weight loss. Int J Biochem Cell Biol 38:1561–1570
Ross PJ, Ashely S, Norton A et al (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 90:1905–1911
Ravasco P, Monteiro-Grillo I, Vidal PM et al (2005) Dietary counseling improves patients outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 23:1431–1438
Linee guida SINPE per la Nutrizione Artificiale Ospedaliera (2002) Rivista Italiana di Nutrizione Parenterale ed Enterale S1–S171
Arends J, Bodoky G, Bozzetti F et al (2006) ESPEN guidelines on adult enteral nutrition: non-surgical oncology. Clin Nutr 25:245–259
Muscaritoli M, Grieco G, Capria S, Iori AP, Rossi Fanelli F (2002) Nutritional and metabolic support in patients undergoing bone marrow transplantation. Am J Clin Nutr 75:183–190
Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M, ESPEN (2009) ESPEN Guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr 28:445–454
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muscaritoli, M., Molfino, A., Gioia, G. et al. The “parallel pathway”: a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med 6, 105–112 (2011). https://doi.org/10.1007/s11739-010-0426-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-010-0426-1